Jeffrey D Feldman
Overview
Explore the profile of Jeffrey D Feldman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
44
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smith K, Panlilio L, Sharma A, McCurdy C, Feldman J, Mukhopadhyay S, et al.
Drug Alcohol Depend
. 2024 Oct;
264:112460.
PMID: 39405600
Background And Aims: Using ecological momentary assessment (EMA), we undertook a natural experiment wherein kratom-product variability was a tool to assess kratom dose-response relationships based on product form and alkaloid...
2.
Zamarripa C, Spindle T, Panlilio L, Strickland J, Feldman J, Novak M, et al.
Traffic Inj Prev
. 2024 Mar;
25(4):594-603.
PMID: 38497810
Objectives: Despite widespread kratom use, there is a lack of knowledge regarding its effects on driving. We evaluated the self-reported driving behaviors of kratom consumers and assessed their simulated-driving performance...
3.
Smith K, Panlilio L, Feldman J, Grundmann O, Dunn K, McCurdy C, et al.
JAMA Netw Open
. 2024 Jan;
7(1):e2353401.
PMID: 38277146
Importance: Kratom products, which are sold legally in most of the US, contain alkaloids with opioidergic, adrenergic, and serotonergic activity. Millions of people use kratom to relieve pain, improve mood,...
4.
Smith K, Rogers J, Sharma A, McCurdy C, Weiss S, Dunn K, et al.
J Addict Med
. 2024 Jan;
18(2):144-152.
PMID: 38174871
Introduction: Use of kratom has outpaced systematic study of its effects, with most studies reliant on retrospective self-report. Methods: We aimed to assess acute effects following kratom use in adults...
5.
Panlilio L, Burgess-Hull A, Feldman J, Rogers J, Tyburski M, Smith K, et al.
J Subst Use Addict Treat
. 2023 Nov;
157:209219.
PMID: 37981240
Introduction: Activity space in people with substance use disorders (SUDs) has been assessed for theoretical reasons and for detection/prevention of relapse. In this observational study, we relate passively obtained activity...
6.
Smith K, Rogers J, Feldman J
Curr Addict Rep
. 2023 Jun;
10(2):262-271.
PMID: 37266191
Purpose Of Review: Use of "kratom" products, derived from the bioactive botanical have increased amidst US polydrug use epidemics. Kratom alkaloids interact with opioid, serotonergic, adrenergic, and other receptors and...
7.
Smith K, Feldman J, Dunn K, McCurdy C, Weiss S, Grundmann O, et al.
Front Pharmacol
. 2023 May;
14:1174139.
PMID: 37214465
Surveys and case reports have documented kratom use in the United States (US) for over a decade. However, those reports have generally not examined in depth the role kratom plays...
8.
Smith K, Feldman J, Dunn K, McCurdy C, Grundmann O, Garcia-Romeu A, et al.
Exp Clin Psychopharmacol
. 2023 May;
32(2):215-227.
PMID: 37213182
The botanical product commonly called "kratom" is still relatively novel to the United States. Like other natural products marketed as supplements, kratom is highly variable, both in terms of the...
9.
Smith K, Dunn K, Epstein D, Feldman J, Garcia-Romeu A, Grundmann O, et al.
Subst Abus
. 2022 Jun;
43(1):1221-1224.
PMID: 35657649
This Letter to the Editor is a response to Broyan and colleagues who recently published a Case Report presenting data on 28 patients in the United States who identified kratom...